Optiver Holding
NAGE

Optiver Holding’s Niagen Bioscience NAGE Stock Holding History

Optiver Holding’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4K Buy
3,563
+3,091
+655% +$12.5K ﹤0.01% 1709
2026
Q1 		$2.08K Buy
472
+144
+44% +$777 ﹤0.01% 1827
2025
Q4 		$2.09K Hold
328
– – ﹤0.01% 1995
2025
Q3 		$3.06K Buy
+328
New +$3.31K ﹤0.01% 2172

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Optiver Holding's NAGE Position: Q2 2026 in Review

Optiver Holding increased its Niagen Bioscience (NAGE) stake by 655% in Q2 2026, buying an estimated $12.5K and bringing the position to 3,563 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Optiver Holding first reported a position in NAGE in Q3 2025 and has held it in 4 quarters since. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Optiver Holding held 3,563 shares of Niagen Bioscience worth $11.4K as of Q2 2026.
  • Optiver Holding bought 3,091 Niagen Bioscience shares in Q2 2026, an estimated $12.5K.
  • Niagen Bioscience made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1709 holding.
  • Optiver Holding first reported a position in Niagen Bioscience in Q3 2025 and has held it in 4 quarters since.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.